Scientists hoping a cure is already on the shelf will test at least 2,000 drugs against the frightening SARS virus, although some doubt anything they find will stop the flu-like disease once it gets a ...
In a recent study published in the Molecular Therapy journal, researchers assessed the efficacy of the scFv76 antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lung damage.
JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Scientists in search of a SARS cure have narrowed their focus to several dozen drugs that appear to have the best chance of stopping the deadly respiratory virus, but they have abandoned plans to test ...
FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a ...
ROME - Scientists may have solved the chemical riddle of why the SARS virus causes such a deadly pneumonia and have developed a simple therapy that promises to decrease the extraordinarily high death ...
In a recent study posted to the bioRxiv* preprint server, researchers in Australia explored the molecular mechanisms of the pulmonary and cardiac complications caused by severe acute respiratory ...
HONG KONG - Health officials announced a sharp rise Monday in cases of a flu-like disease at a Hong Kong apartment complex and slapped a 10-day quarantine on one building as they scrambled to contain ...
Donald Drakeman GS '88, politics professor and former lawyer, is now at the forefront of developing a treatment for Severe Acute Respiratory Syndrome. His company, Princeton-based pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback